Events

Careers with impact: working in ML applied drug discovery

One of the unexpected outcomes of the COVID-19 pandemic has been that it has made technology talent aware of the opportunities to use technology to tackle some of the world’s most important and pressing healthcare challenges. 


4th November 2020 | 5.30pm UK time - 12:30pm NYC Time

While interest in joining the industry has increased, many are prevented from taking the leap due to a belief that they do not possess the necessary scientific knowledge. This invisible door is preventing talented people from entering the industry. Worryingly, this problem could be amplified for women in tech, who are already less likely to apply for a role they’re not 100% qualified for.

This meetup will look to demystify AI in drug discovery in order to empower female tech talent to take the leap into this important growth industry. We will counter preconceptions that only those with scientific knowledge can join, by showcasing how we work at BenevolentAI, where we bring together cross-functional teams of machine learning engineers, AI scientists, data scientists and informaticians to co-create our AI platform for drug discovery, alongside our seasoned drug discoverers.

This is a free event and we’d love you to join us for an evening of open dialogue and ideas exchange. 

→ Register here

Event agenda

17:30 – Grab a drink of your choice, get comfy and logon for an intro from Sam

17:35 – 19:55 – Panel discussion part I: countering preconceptions that only those with scientific knowledge can join the drug discovery industry

17:55 - 18:15 – Panel discussion part II: exploring the importance of diverse skills and experiences in AI applied drug discovery, and discussing practical actions to building diverse and inclusive teams.

18:15 - 18:20 – Q&As

18:20 - 18:50 – Split into virtual rooms for networking and a Q&A opportunity with the Benevolent team.


Speakers:

Ana Leite | Lead Bioinformatic Data Scientist

Aylin Cakiroglu | Senior AI Scientist

Paidi Creed | Director, AI Science

Saee Paliwal | Lead AI Scientist

Sam Coulter (Moderator) | Talent Acquisition Specialist


More Posts

You Might Also Like

News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021